Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 777 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: attention placebo Clear all
Recruiting Phase 3 Interventional

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

NCT07095894
View directory record Official record
Conditions
Myopia
Interventions
Atropine, Spectacles with HAL, Placebo Eyedrops
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
5 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Fullerton, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030
View directory record Official record
Conditions
ADHD
Interventions
PRC-063 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Purdue Pharma, Canada
Industry
Eligibility
18 Years to 60 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)

NCT00453921
View directory record Official record
Conditions
Brain Injury
Interventions
Methylphenidate, Memory and Attention Training, Placebo as both treatments
Drug · Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Indianapolis, Indiana • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

NCT00069017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI-522, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 7, 2026, 11:29 AM EDT
Recruiting Phase 2 Interventional

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855
View directory record Official record
Conditions
Membranous Nephropathy, Nephrotic Syndrome
Interventions
Belimumab, Placebo for Belimumab, Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients

NCT00796952
View directory record Official record
Conditions
Head & Neck Cancer
Interventions
focused attention sessions, Valchuff, Pharyngocise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 7, 2026, 11:29 AM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 7, 2026, 11:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36

NCT04424693
View directory record Official record
Conditions
Pre-Eclampsia, Diphtheria, Tetanus and Pertussis Vaccine Reaction
Interventions
Tdap Vaccine Administration
Drug
Lead sponsor
Institute of Arthritis Research
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

NCT00983814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Droxidopa+Carbidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

NCT02763579
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Results available

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

NCT00716274
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Dyslexia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hostile Bias Modification Training Online Study II

NCT04015440
View directory record Official record
Conditions
Aggression, Anger, Emotion Regulation, Self-Control, Stress
Interventions
HBMT, Other Training
Behavioral
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 7, 2026, 11:29 AM EDT
Terminated Phase 3 Interventional

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

NCT00841126
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Magnesium iron hydroxycarbonate, Lanthanum carbonate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

NCT00367835
View directory record Official record
Conditions
ADHD
Interventions
SPD503 (Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02257216
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Vayarin®, Placebo
Other
Lead sponsor
Enzymotec
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Marietta, Georgia • Mount Kisco, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional

CBT Insomnia Teens: Augmenting SSRIs to Improve Youth Depression

NCT02290496
View directory record Official record
Conditions
Insomnia, Depression
Interventions
CBT for Insomnia (CBT-I), Sleep Hygiene (SH)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
12 Years to 19 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01546142
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
30
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HELP-HY: Health Education and sLeep Program in HYpertension

NCT03255746
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Sleep Enhancement, Health Education
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041
View directory record Official record
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women

NCT01143194
View directory record Official record
Conditions
Attention, Memory, Alertness
Interventions
oréVida™, Placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
35 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Barriers to Physical Activity in People With Type 2 Diabetes

NCT01701570
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo Attention Control, Supervised Exercise Training
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 7, 2026, 11:29 AM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

NCT04219995
View directory record Official record
Conditions
Intractable Epilepsy, Convulsive Seizures
Interventions
methylprednisolone sodium succinate, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 7, 2026, 11:29 AM EDT
Completed Not applicable Interventional

A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD

NCT03066505
View directory record Official record
Conditions
ADHD
Interventions
Active MeRT Treatment, Sham MeRT Treatment
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years to 25 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 7, 2026, 11:29 AM EDT